Current Edition

cash

After failure, Zynerba shifts gears to save cash

Zynerba Pharmaceuticals on Thursday announced negative topline results from a Phase 1 safety and dosing study of its transdermal tetrahydrocannabinol patch ZYN001, sending shares down …

Continue Reading →